ContraFect (CFRX) Posts Earnings Results, Beats Estimates By $0.17 EPS

ContraFect (NASDAQ:CFRX) released its quarterly earnings results on Thursday. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.17, MarketWatch Earnings reports.

Shares of NASDAQ:CFRX opened at $0.40 on Friday. The stock has a market cap of $32.16 million, a price-to-earnings ratio of -1.08 and a beta of -0.49. ContraFect has a 1-year low of $0.35 and a 1-year high of $2.93.

A hedge fund recently raised its stake in ContraFect stock. Geode Capital Management LLC lifted its holdings in ContraFect Corp (NASDAQ:CFRX) by 8.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 377,908 shares of the biotechnology company’s stock after purchasing an additional 29,009 shares during the quarter. Geode Capital Management LLC owned about 0.48% of ContraFect worth $578,000 as of its most recent SEC filing. 55.57% of the stock is currently owned by institutional investors and hedge funds.

Separately, ValuEngine cut ContraFect from a “buy” rating to a “hold” rating in a report on Thursday, December 6th.

WARNING: “ContraFect (CFRX) Posts Earnings Results, Beats Estimates By $0.17 EPS” was first reported by Markets Daily and is owned by of Markets Daily. If you are accessing this article on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The original version of this article can be viewed at https://www.themarketsdaily.com/2019/03/15/contrafect-cfrx-posts-earnings-results-beats-estimates-by-0-17-eps.html.

About ContraFect

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

Further Reading: Stock Selection – What is cash flow?

Earnings History for ContraFect (NASDAQ:CFRX)

Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.